Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf Schmidt

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Bioorganic & Medicinal Chemistry|August 2, 2023
Discovery of quinazoline HPK1 inhibitors with high cellular potencyMomar Toure, Theresa Johnson, Bin Li, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Cell|April 21, 2026
Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cellsUjjwal Rathore, Eli Dugan, Hunter Thornton, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Bioorganic & Medicinal Chemistry|August 2, 2023
Discovery of quinazoline HPK1 inhibitors with high cellular potencyMomar Toure, Theresa Johnson, Bin Li, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Cell|April 21, 2026
Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cellsUjjwal Rathore, Eli Dugan, Hunter Thornton, et al.
Pageof 9